2 ratings / 3.5 average

Drug-Eluting Stents in ACS

Eric L Wallace, DO, Matthew E Wiisanen, MD, and Khaled M Ziada, MD

Significant clinical benefit has been demonstrated in patients with ACS undergoing percutaneous coronary intervention with optimal medical therapy as part of an early invasive strategy. Bare-metal stents (BMS) have been shown to improve clinical outcomes compared with balloon angioplasty, but are also associated with restenosis and the need for repeat revascularization. Drug-eluting stents (DES) have subsequently been developed to reduce the occurrence of restenosis; however, there is debate about their true efficacy and long-term safety. In this review, clinical trials investigating outcomes with DES compared with BMS are discussed in the setting of ACS. Acute Coronary Syndromes 2011;10(3):109–13.

Return to top